Coronavirus Disease 2019 (COVID-19) is the most dramatic pandemic of the new
millennium, and it has globally urged the scientific research without precedents.
More recently, the International Fetal and Newborn Growth Consortium for the 21st
Century (INTERGROWTH-21st) has published the results of the INTERCOVID
multinational cohort study, involving 43 institutions from 18 different countries
(Argentina, Brazil, Egypt, France, Ghana, India, Indonesia, Italy, Japan, Mexico,
Nigeria, North Macedonia, Pakistan, Russia, Spain, Switzerland, United Kingdom,
United States), in which 706 COVID-19 pregnant women and 1424 COVID-free pregnant
women have been enrolled and studied from March to October 2020 [1]. COVID-19
women are resulted at higher risk for severe infections, intensive care unit
admission, preeclampsia/eclampsia, maternal mortality, preterm birth, medically
indicated preterm birth, severe neonatal morbidity index, and severe perinatal
morbidity and mortality index [1]. Interestingly, COVID-19 women already at high
risk for preeclampsia because of preexisting overweight, diabetes, hypertension,
and cardiac or chronic respiratory diseases, have showed almost 4 times greater
risk of developing preeclampsia/eclampsia [1]. Therefore, these findings should
alert pregnant women and clinicians to implement strictly all the recommended
COVID-19 preventive measures, such as respiratory hygiene by filtering facepiece
2 or 3 (FFP2 or FFP3) masks, physical distancing at least 1 meter, avoid
interacting with sick people and spending time in crowded places, cleaning hands
with sanitizer or soap and water. But what are the biomolecular reasons behind
these results? There are essentially two orders of reasons, the former concerns
with the immune system rearrangement of pregnant women, while the latter with the
angiotensin-converting system of blood pressure control. As well known, during a
healthy pregnancy there is an important shift from the cell-mediated immunity,
the so-called T-helper 1 (T1) response, towards the humoral one, also
termed T-helper 2 (T2) response, in order to protect the fetus by
rejection, ensuring full maternal immune tolerance [2, 3]. In this way, the
immune system of a pregnant woman is T1 depolarized and T2 polarized,
a default defense less effective against intracellular or phagocytosable
pathogens, such as viruses [4]. If we consider that the most serious COVID-19
occur precisely in those patients with a deficient T1 immune response, due
to individual predisposition, pre-existing pathologies, or advanced age [4, 5, 6], a
logical explanation about the higher risk for severe infections in pregnant women
is obtained (Fig. 1). In addition, we know that Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2) enters the cells via angiotensin-converting enzyme 2
(ACE2) [7, 8], located in various tissues including the placenta, where it can
exert its action and then pass into the fetus [9, 10, 11]. The placenta is a
transient organ devoid of autonomic nerve terminals, and its main regulatory
mechanism of perfusion is represented by the angiotensin-converting system [12].
Placental ACE2 exhibits a gestational age-dependent expression profile with
higher levels in the first trimester, which so appears to be the most vulnerable
gestational period for SARS-CoV-2 infection [13]. According to a secondary
analysis of the World Association of Perinatal Medicine (WAPM) study, a
multinational cohort study on 388 consecutive singleton pregnancies with
laboratory-confirmed COVID-19 from February to April 2020 belonging to 73 centers
spread across 22 different countries (Argentina, Australia, Belgium, Brazil,
Colombia, Czech Republic, Finland, Germany, Greece, Israel, Italy, North
Macedonia, Peru, Portugal, Republic of Kosovo, Romania, Russia, Serbia, Slovenia,
Spain, Turkey, United States), early gestational age at infection, maternal
ventilatory support, and low birthweight are the main determinants of adverse
perinatal outcomes in fetuses with maternal COVID-19 [14]. Physiologically, ACE2
lowers blood pressure by catalyzing the hydrolysis of angiotensin 2 (A2), a
powerful vasoconstrictor, into angiotensin 1-7 (A1-7), a vasodilator peptide [7].
The extracellular domain of ACE2 is cleaved from the transmembrane domain by the
enzyme sheddase, and its soluble form (sACE2) is released into the
bloodstream and, ultimately, excreted in the urine [15]. The binding of
SARS-CoV-2 spike protein and free-floating spike proteins with ubiquitous ACE2
receptors and sACE2 results in a down-regulation or loss of function [16], with
subsequent onset of a blood pressure framework dominated by A2 prone to
inflammation and hypertension (Fig. 1), which allows to explain well the higher
risk to develop preeclampsia/eclampsia in COVID-19 pregnant women. The occurrence
of preeclampsia/eclampsia in general population is influenced by maternal race;
likewise, the probability of developing a moderate or severe form of COVID-19
among pregnant women correlates with ethnicity, being higher in Hispanic than
non-Hispanic females [17]. By virtue of all this new evidence, the International
Society of Infectious Diseases in Obstetrics and Gynecology (ISIDOG) considers
pregnancy as a risk factor for serious complications from SARS-CoV-2 infection,
and pregnant women as a priority category in receiving COVID-19 vaccination [18].
Currently available data favor modRNA-based vaccines above vector-based vaccines
during pregnancy and breastfeeding, although long-term pharmacovigilance is still
lacking for both [19]; however, preliminary findings of modRNA vaccine safety in
pregnant persons are encouraging to date [20].
Fig. 1.
The immune system during a healthy pregnancy is
T2 polarized, a default defense that makes the pregnant woman more
vulnerable to severe SARS-CoV-2 infection. Moreover, the interaction between the
spike protein and ACE2/sACE2 creates an imbalance towards A2, which higher risk
to develop preeclampsia/eclampsia [the 3D illustration of SARS-CoV-2 has
been drawn by Alissa Eckert, MS, and Dan Higgins, MAM, at the Centers for Disease
Control and Prevention (CDC) of Atlanta, Georgia, USA, placed in the public
domain and thus free of any copyright restrictions].